Edgewise Therapeutics
Stephen Schlachter is a Senior Scientist in Chemistry at Edgewise Therapeutics. Prior to joining Edgewise Therapeutics, Stephen worked as a Research Scientist at Peloton Therapeutics, Array BioPharma Inc., and Amgen. Stephen began their career as a Research Associate at Pfizer after completing their Bachelor of Science in Organic Chemistry from The University of Texas at Austin and the University of Nebraska-Lincoln.
Edgewise Therapeutics
1 followers
Edgewise Therapeutics is a biotechnology company harnessing proven expertise and understanding of skeletal muscle physiology to develop novel, transformative therapies for serious muscle diseases. Based in Boulder, Colorado, we have built a state-of-the-art muscle research facility to capitalize on new insights into the nature and consequences of muscle adaptation and injury with disease. Edgewise recently closed it’s Series B financing round which will support the advancement of Edgewise Therapeutic’s lead product candidate into clinical development for Duchenne and Becker Muscular Dystrophy (DMD and BMD) as well as expansion of the company’s pipeline. The company’s leadership team has founded multiple biotechnology startups, several of which have gone on to become publicly-traded companies and brings to bear a depth of experience in drug discovery, development and commercialization.